Company
Pulmonx
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
5
510(k), De Novo and PMA
Device trials
15
As lead sponsor, any status
Adverse event reports
99
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
Pulmonx is on our public-company list (ticker LUNG). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
LUNG
Nasdaq · Pulmonx Corp
Public float
$101M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$90.5M
Fiscal year ending Dec 31, 2025
Net income
-$54.0M
Fiscal year ending Dec 31, 2025
R&D spending
$19.5M
Fiscal year ending Dec 31, 2025
Cash
$52.7M
As of Sep 30, 2026
Long-term debt
$37.8M
As of Sep 30, 2026
Shares outstanding
43.6M
As of Oct 29, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2023 | – | – | $20.0M | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K253096 · Decided Feb 13, 2026 · 143 days after receipt
Device type: Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector) (CBI) · Anesthesiology & Respiratory
K222340 · Decided Dec 1, 2022 · 120 days after receipt
Device type: Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector) (CBI) · Anesthesiology & Respiratory
- Lung Image AnalysisThird-party review510(k)
K212494 · Decided Sep 2, 2021 · 24 days after receipt
Device type: System, X-Ray, Tomography, Computed (JAK) · Radiology & Imaging
2 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06035120 · 200 participants (planned) · Start Feb 22, 2024 · Primary completion Jun 30, 2027
Device: AeriSeal System · For: Emphysema, Pulmonary; Emphysema or COPD
Sites: Phoenix, Arizona; Loveland, Colorado; Hartford, Connecticut · 38 sites in all
NCT06332885 · 140 participants (planned) · Start Mar 12, 2024 · Primary completion Mar 31, 2027
Device: Zephyr Endobronchial Valve · For: Emphysema; COPD; Severe Emphysema
Sites: Aichi, Japan; Gifu, Japan; Kanagawa, Japan · 17 sites in all
- Zephyr Valve Registry (ZEVR)Active, not recruiting
NCT04186546 · 150 participants (planned) · Start Nov 25, 2019 · Primary completion Dec 31, 2026
Device: Zephyr Valve Procedure · For: Emphysema
Sites: Birmingham, Alabama; Chicago, Illinois; Winfield, Illinois · 11 sites in all
12 more trials with a free account
Reports received
99
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
12
12% of reports
Injury reports
74
75% of reports
Death reports
13
13% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 8 | 2 | 0 |
| Jan 24 | 0 | 7 | 0 | 0 |
| Feb 24 | 0 | 9 | 3 | 0 |
| Mar 24 | 0 | 2 | 3 | 0 |
| Apr 24 | 3 | 7 | 3 | 0 |
| May 24 | 3 | 0 | 2 | 0 |
| Jun 24 | 1 | 17 | 0 | 0 |
| Jul 24 | 0 | 11 | 0 | 0 |
| Aug 24 | 0 | 1 | 3 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 1 | 6 | 0 | 0 |
| Nov 24 | 1 | 15 | 2 | 0 |
| Dec 24 | 0 | 21 | 1 | 0 |
| Jan 25 | 0 | 2 | 0 | 0 |
| Feb 25 | 1 | 3 | 0 | 0 |
| Mar 25 | 1 | 3 | 0 | 0 |
| Apr 25 | 0 | 6 | 7 | 0 |
| May 25 | 1 | 1 | 0 | 0 |
| Jun 25 | 0 | 1 | 1 | 0 |
| Jul 25 | 0 | 0 | 1 | 0 |
| Aug 25 | 3 | 4 | 0 | 0 |
| Sep 25 | 2 | 14 | 0 | 0 |
| Oct 25 | 1 | 3 | 0 | 0 |
| Nov 25 | 0 | 8 | 4 | 0 |
| Dec 25 | 1 | 12 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 2 | 8 | 0 | 0 |
| Mar 26 | 2 | 0 | 0 | 0 |
| Apr 26 | 2 | 3 | 0 | 0 |
| May 26 | 0 | 7 | 0 | 0 |
| Jun 26 | 3 | 11 | 0 | 0 |
| Jul 26 | 2 | 6 | 3 | 0 |
| Aug 26 | 0 | 1 | 0 | 0 |
| Sep 26 | 0 | 11 | 3 | 0 |
| Oct 26 | 0 | 7 | 3 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Zephyr Endobronchial Valve (EBV) 5.5-LP, REF: EBV-TS-5.5-LPOpen, Classified
Z-0235-2024 · Started Aug 31, 2023 · Posted by FDA Nov 6, 2023
Reason given: Endobronchial implant devices may have been labeled with a shortened expiration date but they can be used until the correct expiration date: 08 December 2024.
Cause as FDA categorized it: Error in labeling · Device type: Valve, Pulmonary (NJK)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.